Patient-reported outcome claims in European and United States orphan drug approvals

Purpose: We aimed to evaluate the rate of usage and the kind of patient-reported outcome (PRO) claims in orphan drug approvals from the European Medicines Agency (EMA) dated between 1/1/2012 and 31/12/2016 and to compare them to those from the US Food and Drug Administration (FDA). Methods: Orphan d...

Full description

Saved in:
Bibliographic Details
Main Authors: Szymon Jarosławski, Pascal Auquier, Borislav Borissov, Claude Dussart, Mondher Toumi
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Online Access:http://dx.doi.org/10.1080/20016689.2018.1542920
Tags: Add Tag
No Tags, Be the first to tag this record!